Rodin Therapeutics Acquisition

11/18/2019

M&A

$950,000,000

Alkermes intends to advance Investigational New Drug (IND)-enabling activities for lead preclinical assets in the Rodin development candidate portfolio, potentially prioritizing those ahead of future clinical development of Rodin's initial clinical candidate. Alkermes also plans to continue Rodin's preclinical research program focused on the subset of frontotemporal dementia patients with an inherited mutation of the progranulin gene (FTD-GRN) and exploratory work in hematological disorders and oncology. Rodin's security holders will receive an upfront cash payment of $100 million upon the closing of the transaction and will be eligible to receive future payments of up to $850 million upon achievement by Rodin's development candidates of certain specified clinical and regulatory milestones, and attainment of certain sales thresholds.

Acquired or Merged

Biopharmaceutical

300 Technology Sq. 8th Floor
Cambridge, MA 02139
USA

Not Recorded

Rodin is harnessing the power of epigenetic regulation of neuronal function to treat diseases of the brain. We believe modulation of selective epigenetic regulatory processes can restore synaptic plasticity and cognitive function in degenerative brain diseases, as well as to aid the brain in reducing negative associations with traumatic memories.